Tabell
Hovedbudskap |
|
- 1.
Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186 – 200.
- 2.
Spigset O. Cytokrom P-450-systemet Tidsskr Nor Lægeforen 2001; 121: 3296 – 8.
- 3.
Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103 – 13.
- 4.
Scordo MG, Spina E, Facciola G et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147: 300 – 5.
- 5.
Spigset O. Bruk av legemidler ved nedsatt leverfunksjon Tidsskr Nor Lægeforen 2005; 125: 2645 – 6.
- 6.
Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196 – 201.
- 7.
Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243 – 65.
- 8.
Rotzinger S, Bourin M, Akimoto Y et al. Metabolism of some «second»- and «fourth»-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999; 19: 427 – 42.
- 9.
Otton SV, Ball SE, Cheung SW et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149 – 56.
- 10.
Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31: 493 – 502.
- 11.
Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39: 121 – 7.
- 12.
Doran A, Obach RS, Smith BJ et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33: 165 – 74.
- 13.
Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004; 7: 415 – 9.
- 14.
de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15 – 27.